Welcome to Diagnostics Accelerator (DxA) Day 2025!
We are thrilled to welcome you to DxA Day. This meeting promises to be another exciting opportunity for DxA-funded investigators and experts to share and discuss progress on blood, digital and speech biomarkers for Alzheimer’s.
Alzheimer’s treatments are entering a new phase that will hinge on combination therapy, precision medicine, and lifestyle interventions. Diagnostics and biomarkers will be integral to the future of Alzheimer’s care, paving the way for earlier detection and intervention. This year, we will hear from leading scientists, entrepreneurs, startups, investors, and others who are part of this collaborative effort.
Since its launch in 2018, the DxA has fostered a bold vision for developing accessible and affordable biomarkers for Alzheimer’s disease and related dementias by providing resources to the world’s brightest scientists. To date, the $100 million global research initiative has invested more than $80M for over 70 global research projects, creating a robust portfolio. With two disease-modifying therapies on the market, the need for accessible diagnostics is even more vital as we look to ensure the right drugs are delivered to the right patients at the right time. Biomarkers have proven vital for every phase of the drug discovery and development process, and further advancing the biomarker pipeline by bringing scalable tests to market will be pivotal.
We are grateful for the vision and support of ADDF Co-Founder Leonard A. Lauder and Bill Gates, as well as all funders who bring focus, resources, and urgency to advance the development of diagnostic tools, including the Dolby Family, The Charles and Helen Schwab Foundation, Jeff Bezos, The Association for Frontotemporal Degeneration (AFTD), MacKenzie Scott, The NFL Players Association (NFLPA), Eli Lilly & Company, Biogen, The Shanahan Family Foundation, and others.
We hope you will take this opportunity to connect and collaborate, exchanging ideas to further accelerate research for a future free from Alzheimer’s. We look forward to another thought-provoking and insightful meeting.
Sincerely,


About the Diagnostics Accelerator (DxA)
The Diagnostics Accelerator (DxA), created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias.
This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers.